Original language | English (US) |
---|---|
Pages (from-to) | 2284-2286 |
Number of pages | 3 |
Journal | Journal of the American College of Cardiology |
Volume | 76 |
Issue number | 19 |
DOIs | |
State | Published - Nov 10 2020 |
Bibliographical note
Funding Information:This research was funded by Aria CV. Dr. Gerges has received compensation for scientific symposia from AOPOrphan Pharmaceuticals, Actelion, and GlaxoSmithKline. Dr. Vollmers is the chief technology officer at Aria CV. Drs. Pritzker and Weir serve on the Aria CV scientific advisory board. Mr. Gainor is a consultant for Aria CV. Dr. Scandurra is the chief scientific officer at Aria CV. Dr. Lang has been an investigator in trials for, a consultant for, received research grants from, and been a member of scientific advisory boards for AOPOrphan Pharmaceuticals, Actelion, Merck Sharp & Dohme, AstraZeneca, Medtronic, Ferrer, and United Therapeutics. The authors thank the nurses and technicians of the cardiac catheterization laboratory of the Medical University of Vienna for their support throughout the study.